A share price of Alnylam Pharmaceuticals Inc [ALNY] is currently trading at $339.8, up 2.80%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ALNY shares have gain 4.35% over the last week, with a monthly amount glided 4.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist started tracking the stock with Buy rating on July 21, 2025, and set its price target to $385. On March 31, 2025, Redburn Atlantic initiated with a Buy rating and assigned a price target of $353 on the stock. JP Morgan upgraded its rating to a Overweight and increased its price target to $328 on March 24, 2025. Wolfe Research downgraded its rating to a Underperform. In a note dated August 16, 2024, Goldman upgraded an Buy rating on this stock and boosted its target price from $198 to $370.
Alnylam Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $205.87 and $333.70. Currently, Wall Street analysts expect the stock to reach $361 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $339.8 at the most recent close of the market. An investor can expect a potential return of 6.24% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
Trailing Twelve Months sales for Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] were 2.35B which represents 20.20% growth. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -5.09 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of11.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 333.23 points at the first support level, and at 326.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 346.18, and for the 2nd resistance point, it is at 352.55.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] is 3.04. In addition, the Quick Ratio stands at 2.98 and the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 18.87, the price to book ratio is 383.59.
Transactions by insiders
Recent insider trading involved Greenstreet Yvonne, Chief Executive Officer, that happened on May 30 ’25 when 31640.0 shares were sold. Chief Executive Officer, Greenstreet Yvonne completed a deal on Jun 02 ’25 to sell 19297.0 shares. Meanwhile, Officer Greenstreet Yvonne bought 19297.0 shares on Jun 02 ’25.
